Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160768 · ClinicalTrials.gov registry record
Feasibility of Isolating P16 Expression
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- 85
- Enrollment target
NCT03160768: Completed study, sponsored by St. Jude Children's Research Hospital.
NCT03160768 is a clinical trial that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03160768 has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
Study Summary
Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In mice, both radiation and chemotherapy are known to increase p16. Due to its influence on age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic reserve that may identify patients able to withstand the stressor of chemotherapy (low p16) from those unlikely to tolerate chemotherapy (high p16). That is, expression of p16 may predict physiologic, rather than chronologic, age. Such findings could have implications for care of cancer survivors and treatment decision-making in cancer patients. STUDY OBJECTIVE: This is an observational pilot study to determine the feasibility of isolating p16INK4a in CD3+ T lymphocytes in adults treated with chemotherapy for cancer during childhood.
Primary Outcome
Blood samples will be drawn once at a regularly scheduled follow-up visit. After T cells are isolated, the samples will be sent in one batch for further processing and investigation of p16 expression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2019-05-02 |
What the finished NCT03160768 record still lists
NCT03160768 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03160768 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03160768 about?
NCT03160768 is a clinical study titled "Feasibility of Isolating P16 Expression". Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In mice, both radiation and chemotherapy are known to increase p16. Due to its influence on age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic reserve that may identify pati...
What is the current status of trial NCT03160768?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-05-25. Estimated completion is 2019-05-02.
Who is sponsoring clinical trial NCT03160768?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI